Gujarat Themis Biosyn
361.30
+6.80(+1.92%)
Market Cap₹3,862.80 Cr
PE Ratio86.88
IndustryHealthcare
Company Performance:
1D+1.92%
1M-1.28%
6M+48.40%
1Y+48.40%
5Y+48.40%
View Company Insightsright
Latest news about Gujarat Themis Biosyn
Gujarat Themis Biosyn Reports Q1 FY2026 Results, Announces Board Changes and New API Plant Aug 01, 2025
Gujarat Themis Biosyn reported Q1 FY2026 total income of ₹3,614.72 lakh and net profit of ₹926.16 lakh. The company set September 5, 2025, as the dividend record date. Board changes include appointment of Nihar Parikh as Additional Non-Executive Independent Director and cessation of Siddharth Kusumgar's term. A new API plant in Vapi, Gujarat commenced operations on May 1, 2025, aimed at strengthening the company's position in domestic and export markets.
Gujarat Themis Biosyn Reports Q1 Results, Appoints New Director, and Commences API Plant Operations Aug 01, 2025
Gujarat Themis Biosyn Reports Q1 Results, Announces Board Changes and New API Plant Aug 01, 2025
Gujarat Themis Biosyn Reports Q1 Decline and Board Reshuffles Aug 01, 2025
Gujarat Themis Biosyn Reports Decline in Q4 Financial Performance May 20, 2025
More news about Gujarat Themis Biosyn
06May 25
Gujarat Themis Biosyn Launches Commercial Production at New API Plant
Gujarat Themis Biosyn Ltd (GTBL) has commenced commercial production at its new Active Pharmaceutical Ingredient (API) plant in Gujarat. This strategic move aims to enhance the company's manufacturing capabilities and expand its market reach. The new facility is expected to strengthen GTBL's forward integration initiatives, potentially improving profit margins and supply chain control. The company is focusing on reinforcing its position in key export markets, particularly the United States and Europe. This expansion signifies GTBL's commitment to growth and innovation in the pharmaceutical sector, positioning it to meet increasing global demand for high-quality APIs.
Gujarat Themis Biosyn
361.30
+6.80
(+1.92%)
1 Year Returns:+48.40%
Industry Peers
Sun Pharmaceutical
1,632.70
(-0.53%)
Divis Laboratories
6,164.50
(+0.52%)
Cipla
1,565.20
(+0.08%)
Torrent Pharmaceuticals
3,651.60
(+0.79%)
Dr Reddys Laboratories
1,262.70
(+0.18%)
Mankind Pharma
2,472.40
(-0.01%)
Zydus Life Science
986.50
(-0.23%)
Lupin
1,968.30
(+0.34%)
Abbott
32,590.00
(-2.03%)
Alkem Laboratories
5,346.00
(-0.03%)